Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.077

€0.077

-6.090%
-
-6.090%
-
 
31.03.23 / Tradegate WKN: A1JPJY / Symbol: CLVS / Name: Clovis Oncology / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Clovis Oncology Inc. Stock

Clovis Oncology Inc. took a tumble today and lost €0.000 (-6.090%).
Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Clovis Oncology Inc. is rather balanced.
Our community identified positive and negative aspects for Clovis Oncology Inc. stock for the coming years. 2 users see the criterium "Shareholder structure" as a plus for the Clovis Oncology Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.

Pros and Cons of Clovis Oncology Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Clovis Oncology Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Clovis Oncology Inc. -6.090% 0.000% 0.000% -95.821% 0.000% -98.668% -99.821%
Sorrento Therapeutics Inc. -24.520% 0.000% 0.000% -86.746% -65.296% -83.166% -
Evolus Inc 1.960% 1.961% -5.455% -26.415% 10.638% 103.125% -
Hepion Pharmaceuticals Inc. 1.850% 13.615% -12.460% -39.283% 161.013% -53.529% -

Comments

Buy Clovis Oncology Inc.
Show more

News

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286


Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis